Study Comparing IV Clevidipine and Other IV Blood Pressure Treatments for Adults With Acute Intracerebral Hemorrhage and Stroke

What this Trial Is About

Researchers are evaluating the effectiveness of intravenous clevidipine compared to other intravenous antihypertensive treatments in patients with acute intracerebral hemorrhage ICH who also have high blood pressure. The study focuses on how quickly and effectively these treatments help patients reach a stable systolic blood pressure SBP target within 60 minutes of enrollment. This research aims to improve blood pressure management strategies in stroke patients experiencing ICH, sponsored by the Zeenat Qureshi Stroke Institute. Participants receive either clevidipine injection or an alternate intravenous antihypertensive regimen, typically nicardipine at hospitals not using clevidipine. Clevidipine is started at 1-2 mghour and adjusted every few minutes, with doses generally ranging from 4-6 mghour and not exceeding recommended limits to avoid lipid load issues. The alternate treatment follows institutional standards, starting at 5 mghour and titrating to effect. Treatments are initiated within 12 hours of symptom onset. During the study, participants undergo blood pressure monitoring every 15 minutes to assess the primary outcome of reaching and maintaining the target SBP. The study includes follow-up visits at 90 and 180 days after enrollment to collect additional data. Patients neurological status, stroke severity, and brain imaging are considered for eligibility and monitoring. The total duration of participation extends through these follow-up periods to evaluate longer-term outcomes.

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage